메뉴 건너뛰기




Volumn 13, Issue 8, 2011, Pages 613-620

Overcoming obstacles in risk factor management in type 2 diabetes mellitus

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); DRUG COST; DYSLIPIDEMIA; HEALTH INSURANCE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT FAILURE;

EID: 79960947106     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00490.x     Document Type: Review
Times cited : (18)

References (75)
  • 2
    • 34147124852 scopus 로고    scopus 로고
    • Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes
    • Pratley R. Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Endocrinol Metab Clin North Am. 2006;35(suppl 1):6-11.
    • (2006) Endocrinol Metab Clin North Am. , vol.35 , Issue.SUPPL. 1 , pp. 6-11
    • Pratley, R.1
  • 3
    • 58149468464 scopus 로고    scopus 로고
    • Can newer therapies delay the progression of type 2 diabetes mellitus?
    • Horton ES. Can newer therapies delay the progression of type 2 diabetes mellitus? Endocr Pract. 2008;14:625-638.
    • (2008) Endocr Pract. , vol.14 , pp. 625-638
    • Horton, E.S.1
  • 4
    • 75149180515 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2010
    • American Diabetes Association.
    • American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(suppl 1):S11-S61.
    • (2010) Diabetes Care. , vol.33 , Issue.SUPPL. 1
  • 5
    • 77649091668 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus
    • Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.
    • (2007) Endocr Pract. , vol.13 , Issue.SUPPL. 1 , pp. 1-68
    • Rodbard, H.W.1    Blonde, L.2    Braithwaite, S.S.3
  • 6
    • 38949210220 scopus 로고    scopus 로고
    • Effect of a multifactorial intervention on mortality in type 2 diabetes
    • Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
    • (2008) N Engl J Med. , vol.358 , pp. 580-591
    • Gaede, P.1    Lund-Andersen, H.2    Parving, H.H.3    Pedersen, O.4
  • 7
    • 0037472879 scopus 로고    scopus 로고
    • Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    • Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
    • (2003) N Engl J Med. , vol.348 , pp. 383-393
    • Gaede, P.1    Vedel, P.2    Larsen, N.3
  • 9
    • 0347133334 scopus 로고    scopus 로고
    • Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes
    • Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
    • (2004) JAMA. , vol.291 , pp. 335-342
    • Saydah, S.H.1    Fradkin, J.2    Cowie, C.C.3
  • 11
    • 3042714557 scopus 로고    scopus 로고
    • The burden of treatment failure in type 2 diabetes
    • Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.
    • (2004) Diabetes Care. , vol.27 , pp. 1535-1540
    • Brown, J.B.1    Nichols, G.A.2    Perry, A.3
  • 12
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
    • (2007) N Engl J Med. , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 13
    • 70350051492 scopus 로고    scopus 로고
    • Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors
    • Mann DM, Woodward M, Ye F, et al. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med. 2009;169:1718-1720.
    • (2009) Arch Intern Med. , vol.169 , pp. 1718-1720
    • Mann, D.M.1    Woodward, M.2    Ye, F.3
  • 14
    • 75549091263 scopus 로고    scopus 로고
    • Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control
    • Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
    • (2009) Endocr Pract. , vol.15 , pp. 540-559
    • Rodbard, H.W.1    Jellinger, P.S.2    Davidson, J.A.3
  • 15
    • 37749000859 scopus 로고    scopus 로고
    • Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study
    • Bertoni AG, Clark JM, Feeney P, et al. Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. J Diabetes Complications. 2008;22:1-9.
    • (2008) J Diabetes Complications. , vol.22 , pp. 1-9
    • Bertoni, A.G.1    Clark, J.M.2    Feeney, P.3
  • 16
    • 12844281026 scopus 로고    scopus 로고
    • Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change
    • University HealthSystem Consortium Diabetes Benchmarking Project Team.
    • Grant RW, Buse JB, Meigs JB; University HealthSystem Consortium Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337-442.
    • (2005) Diabetes Care. , vol.28 , pp. 337-442
    • Grant, R.W.1    Buse, J.B.2    Meigs, J.B.3
  • 17
    • 33749006625 scopus 로고    scopus 로고
    • Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus
    • Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836-1841.
    • (2006) Arch Intern Med. , vol.166 , pp. 1836-1841
    • Ho, P.M.1    Rumsfeld, J.S.2    Masoudi, F.A.3
  • 18
    • 17844391245 scopus 로고    scopus 로고
    • Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus
    • Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(suppl 5A):27S-34S.
    • (2005) Am J Med. , vol.118 , Issue.SUPPL. 5A
    • Rubin, R.R.1
  • 19
    • 34249300509 scopus 로고    scopus 로고
    • Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors
    • Siminerio L. Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors. Diabetes Educ. 2007;33(suppl 5):111S-113S.
    • (2007) Diabetes Educ. , vol.33 , Issue.SUPPL. 5
    • Siminerio, L.1
  • 20
    • 0842311565 scopus 로고    scopus 로고
    • Problems paying out-of-pocket medication costs among older adults with diabetes
    • Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27:384-391.
    • (2004) Diabetes Care. , vol.27 , pp. 384-391
    • Piette, J.D.1    Heisler, M.2    Wagner, T.H.3
  • 21
    • 70449677664 scopus 로고    scopus 로고
    • Cost-related nonadherence to medications among patients with diabetes and chronic pain: factors beyond finances
    • Kurlander JE, Kerr EA, Krein S, et al. Cost-related nonadherence to medications among patients with diabetes and chronic pain: factors beyond finances. Diabetes Care. 2009;32:2143-2148.
    • (2009) Diabetes Care. , vol.32 , pp. 2143-2148
    • Kurlander, J.E.1    Kerr, E.A.2    Krein, S.3
  • 22
    • 53849118827 scopus 로고    scopus 로고
    • Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications
    • Barron J, Wahl P, Fisher M, Plauschinat C. Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications. P T. 2008;33:532-553.
    • (2008) P T. , vol.33 , pp. 532-553
    • Barron, J.1    Wahl, P.2    Fisher, M.3    Plauschinat, C.4
  • 23
    • 69449103894 scopus 로고    scopus 로고
    • Effect of patient medication cost share on adherence and glycemic control
    • Hunt J, Rozenfeld Y, Shenolikar R. Effect of patient medication cost share on adherence and glycemic control. Manag Care. 2009;18:47-53.
    • (2009) Manag Care. , vol.18 , pp. 47-53
    • Hunt, J.1    Rozenfeld, Y.2    Shenolikar, R.3
  • 24
    • 0032837107 scopus 로고    scopus 로고
    • Diabetes in urban African-Americans. XV. Identification of barriers to provider adherence to management protocols
    • El-Kebbi IM, Ziemer DC, Gallina DL, et al. Diabetes in urban African-Americans. XV. Identification of barriers to provider adherence to management protocols. Diabetes Care. 1999;22:1617-1620.
    • (1999) Diabetes Care. , vol.22 , pp. 1617-1620
    • El-Kebbi, I.M.1    Ziemer, D.C.2    Gallina, D.L.3
  • 25
    • 0042309664 scopus 로고    scopus 로고
    • Hypertension management in patients with diabetes: the need for more aggressive therapy
    • Berlowitz DR, Ash AS, Hickey EC, et al. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care. 2003;26:355-359.
    • (2003) Diabetes Care. , vol.26 , pp. 355-359
    • Berlowitz, D.R.1    Ash, A.S.2    Hickey, E.C.3
  • 26
    • 0031852544 scopus 로고    scopus 로고
    • Nurse-mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease
    • Becker DM, Raqueno JV, Yook RM, et al. Nurse-mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease. Arch Intern Med. 1998;158:1533-1539.
    • (1998) Arch Intern Med. , vol.158 , pp. 1533-1539
    • Becker, D.M.1    Raqueno, J.V.2    Yook, R.M.3
  • 27
    • 78650430047 scopus 로고    scopus 로고
    • Clinical inertia in patients with T2DM requiring insulin in family practice
    • Harris SB, Kapor J, Lank CN, et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010;56:e418-e424.
    • (2010) Can Fam Physician. , vol.56
    • Harris, S.B.1    Kapor, J.2    Lank, C.N.3
  • 28
    • 1242314755 scopus 로고    scopus 로고
    • Clinical inertia in the management of type 2 diabetes metabolic risk factors
    • Grant RW, Cagliero E, Dubey AK, et al. Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med. 2004;21:150-155.
    • (2004) Diabet Med. , vol.21 , pp. 150-155
    • Grant, R.W.1    Cagliero, E.2    Dubey, A.K.3
  • 29
    • 23944459590 scopus 로고    scopus 로고
    • Clinical inertia contributes to poor diabetes control in a primary care setting
    • Ziemer DC, Miller CD, Rhee MK, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005;31:564-571.
    • (2005) Diabetes Educ. , vol.31 , pp. 564-571
    • Ziemer, D.C.1    Miller, C.D.2    Rhee, M.K.3
  • 30
    • 14744274123 scopus 로고    scopus 로고
    • Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?
    • Shah BR, Hux JE, Laupacis A, et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28:600-606.
    • (2005) Diabetes Care. , vol.28 , pp. 600-606
    • Shah, B.R.1    Hux, J.E.2    Laupacis, A.3
  • 31
    • 34147109354 scopus 로고    scopus 로고
    • Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management
    • Grant R, Adams AS, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care. 2007;30: 807-812.
    • (2007) Diabetes Care. , vol.30 , pp. 807-812
    • Grant, R.1    Adams, A.S.2    Trinacty, C.M.3
  • 32
    • 0029111811 scopus 로고
    • Managing hypertension in general practice: can we do better?
    • Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens. 1995;9(suppl 2):S15-S18.
    • (1995) J Hum Hypertens. , vol.9 , Issue.SUPPL. 2
    • Hosie, J.1    Wiklund, I.2
  • 33
    • 60849117256 scopus 로고    scopus 로고
    • Impact of direct-to-consumer advertising (DTCA) on patient health-related behaviors and issues
    • Polen HH, Khanfar NM, Clauson KA. Impact of direct-to-consumer advertising (DTCA) on patient health-related behaviors and issues. Health Mark Q. 2009;26:42-55.
    • (2009) Health Mark Q. , vol.26 , pp. 42-55
    • Polen, H.H.1    Khanfar, N.M.2    Clauson, K.A.3
  • 34
    • 67649199624 scopus 로고    scopus 로고
    • Clinical practice effect of rosiglitazone discontinuation on glycemic control
    • Fanning EL, Weissman PN, Menditto LA. Clinical practice effect of rosiglitazone discontinuation on glycemic control. Endocr Pract. 2009;15:270-272.
    • (2009) Endocr Pract. , vol.15 , pp. 270-272
    • Fanning, E.L.1    Weissman, P.N.2    Menditto, L.A.3
  • 35
    • 68949214466 scopus 로고    scopus 로고
    • Lay media reporting of rosiglitazone risk: extent, messaging and quality of reporting
    • Rabi DM, Lewin AM, Brown GE, et al. Lay media reporting of rosiglitazone risk: extent, messaging and quality of reporting. Cardiovasc Diabetol. 2009;8:40.
    • (2009) Cardiovasc Diabetol. , vol.8 , pp. 40
    • Rabi, D.M.1    Lewin, A.M.2    Brown, G.E.3
  • 36
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering in type 2 diabetes
    • Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
    • (2008) N Engl J Med. , vol.358 , pp. 2545-2559
    • Gerstein, H.C.1    Miller, M.E.2    Byington, R.P.3
  • 37
    • 58149389215 scopus 로고    scopus 로고
    • Glucose control and vascular complications in veterans with type 2 diabetes
    • Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
    • (2009) N Engl J Med. , vol.360 , pp. 129-139
    • Duckworth, W.1    Abraira, C.2    Moritz, T.3
  • 38
    • 45149133036 scopus 로고    scopus 로고
    • Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    • Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
    • (2008) N Engl J Med. , vol.358 , pp. 2560-2572
    • Patel, A.1    MacMahon, S.2    Chalmers, J.3
  • 39
    • 79960962493 scopus 로고    scopus 로고
    • Baseline characteristics and mortality in ACCORD (abstract no. 88-OR). American Diabetes Association 69th Scientific Sessions, New Orleans (LA), June 5-9, 2009.
    • Calles J, Banerji M, Bonds DE, et al. Baseline characteristics and mortality in ACCORD (abstract no. 88-OR). American Diabetes Association 69th Scientific Sessions, New Orleans (LA), June 5-9, 2009.
    • Calles, J.1    Banerji, M.2    Bonds, D.E.3
  • 40
    • 77954159481 scopus 로고    scopus 로고
    • Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial
    • Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33:983-990.
    • (2010) Diabetes Care. , vol.33 , pp. 983-990
    • Riddle, M.C.1    Ambrosius, W.T.2    Brillon, D.J.3
  • 41
    • 58149301489 scopus 로고    scopus 로고
    • Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association
    • Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53:298-304.
    • (2009) J Am Coll Cardiol. , vol.53 , pp. 298-304
    • Skyler, J.S.1    Bergenstal, R.2    Bonow, R.O.3
  • 42
    • 68449104156 scopus 로고    scopus 로고
    • Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study
    • Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732-1744.
    • (2009) Diabetologia. , vol.52 , pp. 1732-1744
    • Hemkens, L.G.1    Grouven, U.2    Bender, R.3
  • 43
    • 68449094325 scopus 로고    scopus 로고
    • The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    • Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766-1777.
    • (2009) Diabetologia. , vol.52 , pp. 1766-1777
    • Currie, C.J.1    Poole, C.D.2    Gale, E.A.3
  • 44
    • 68449094354 scopus 로고    scopus 로고
    • Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
    • Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755-1765.
    • (2009) Diabetologia. , vol.52 , pp. 1755-1765
    • Colhoun, H.M.1
  • 45
    • 68449104625 scopus 로고    scopus 로고
    • Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden
    • Jonasson JM, Ljung R, Talback M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745-1754.
    • (2009) Diabetologia. , vol.52 , pp. 1745-1754
    • Jonasson, J.M.1    Ljung, R.2    Talback, M.3
  • 46
    • 79960954712 scopus 로고    scopus 로고
    • US Food and Drug Administration. FDA Drug Safety Communication: update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. .
    • US Food and Drug Administration. FDA Drug Safety Communication: update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. 2011.
    • (2011)
  • 47
    • 0032841673 scopus 로고    scopus 로고
    • Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes
    • Cook CB, Ziemer DC, El-Kebbi IM, et al. Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:1494-1500.
    • (1999) Diabetes Care. , vol.22 , pp. 1494-1500
    • Cook, C.B.1    Ziemer, D.C.2    El-Kebbi, I.M.3
  • 48
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    • UK Prospective Diabetes Study (UKPDS) Group.
    • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
    • (1998) Lancet. , vol.352 , pp. 854-865
  • 49
    • 53749096863 scopus 로고    scopus 로고
    • 10-year follow-up of intensive glucose control in type 2 diabetes
    • Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
    • (2008) N Engl J Med. , vol.359 , pp. 1577-1589
    • Holman, R.R.1    Paul, S.K.2    Bethel, M.A.3
  • 50
    • 67149142042 scopus 로고    scopus 로고
    • A randomized trial of therapies for type 2 diabetes and coronary artery disease
    • Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
    • (2009) N Engl J Med. , vol.360 , pp. 2503-2515
    • Frye, R.L.1    August, P.2    Brooks, M.M.3
  • 51
    • 60449089649 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
    • (2009) Diabetes Care. , vol.32 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 52
    • 0038460302 scopus 로고    scopus 로고
    • The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    • Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
    • (2003) JAMA. , vol.289 , pp. 2560-2572
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 53
    • 33749498694 scopus 로고    scopus 로고
    • Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
    • Rosenstock J, Rood J, Cobitz A, et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2006;8:650-660.
    • (2006) Diabetes Obes Metab. , vol.8 , pp. 650-660
    • Rosenstock, J.1    Rood, J.2    Cobitz, A.3
  • 54
    • 77952083721 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2years in patients with type 2 diabetes
    • Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:442-451.
    • (2010) Diabetes Obes Metab. , vol.12 , pp. 442-451
    • Williams-Herman, D.1    Johnson, J.2    Teng, R.3
  • 55
    • 65549123794 scopus 로고    scopus 로고
    • Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
    • Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611-622.
    • (2009) Diabetes Obes Metab. , vol.11 , pp. 611-622
    • Jadzinsky, M.1    Pfutzner, A.2    Paz-Pacheco, E.3
  • 56
    • 79955015666 scopus 로고    scopus 로고
    • Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76weeks
    • Pfutzner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76weeks. Diabetes Obes Metab. 2011;13:567-576.
    • (2011) Diabetes Obes Metab. , vol.13 , pp. 567-576
    • Pfutzner, A.1    Paz-Pacheco, E.2    Allen, E.3
  • 57
    • 0034641568 scopus 로고    scopus 로고
    • Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
    • Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
    • (2000) BMJ. , vol.321 , pp. 405-412
    • Stratton, I.M.1    Adler, A.I.2    Neil, H.A.3
  • 58
    • 44649098307 scopus 로고    scopus 로고
    • Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
    • Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31: 811-822.
    • (2008) Diabetes Care. , vol.31 , pp. 811-822
    • Brunzell, J.D.1    Davidson, M.2    Furberg, C.D.3
  • 59
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
    • (2010) N Engl J Med. , vol.362 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3
  • 60
    • 77954654472 scopus 로고    scopus 로고
    • Effects of medical therapies on retinopathy progression in type 2 diabetes
    • Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-244.
    • (2010) N Engl J Med. , vol.363 , pp. 233-244
    • Chew, E.Y.1    Ambrosius, W.T.2    Davis, M.D.3
  • 61
    • 0034994041 scopus 로고    scopus 로고
    • Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia
    • Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001;24:467-474.
    • (2001) Clin Cardiol. , vol.24 , pp. 467-474
    • Davidson, M.H.1    Toth, P.2    Weiss, S.3
  • 62
    • 0034802407 scopus 로고    scopus 로고
    • Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively
    • Hunninghake D, Insull W Jr, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158:407-416.
    • (2001) Atherosclerosis. , vol.158 , pp. 407-416
    • Hunninghake, D.1    Insull Jr, W.2    Toth, P.3
  • 63
    • 0035313336 scopus 로고    scopus 로고
    • Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia
    • Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110:352-360.
    • (2001) Am J Med. , vol.110 , pp. 352-360
    • Knapp, H.H.1    Schrott, H.2    Ma, P.3
  • 64
    • 33645098531 scopus 로고    scopus 로고
    • Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review
    • Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006;99: 257-273.
    • (2006) South Med J. , vol.99 , pp. 257-273
    • Insull Jr, W.1
  • 65
    • 25444497513 scopus 로고    scopus 로고
    • Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia
    • McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin. 2005;21:1403-1412.
    • (2005) Curr Med Res Opin. , vol.21 , pp. 1403-1412
    • McKenney, J.1    Jones, M.2    Abby, S.3
  • 66
    • 33751238477 scopus 로고    scopus 로고
    • Lipid-lowering effects of colesevelam HCl in combination with ezetimibe
    • Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin. 2006;22:2191-2200.
    • (2006) Curr Med Res Opin. , vol.22 , pp. 2191-2200
    • Bays, H.1    Rhyne, J.2    Abby, S.3
  • 67
    • 34147131830 scopus 로고    scopus 로고
    • Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance
    • Rivers SM, Kane MP, Busch RS, et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract. 2007;13:11-16.
    • (2007) Endocr Pract. , vol.13 , pp. 11-16
    • Rivers, S.M.1    Kane, M.P.2    Busch, R.S.3
  • 68
    • 25844513563 scopus 로고    scopus 로고
    • Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia
    • Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther. 2005;12:306-310.
    • (2005) Am J Ther. , vol.12 , pp. 306-310
    • Zema, M.J.1
  • 69
    • 55949097996 scopus 로고    scopus 로고
    • Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients
    • Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30:1893-1907.
    • (2008) Clin Ther. , vol.30 , pp. 1893-1907
    • Cheong, C.1    Barner, J.C.2    Lawson, K.A.3    Johnsrud, M.T.4
  • 70
    • 42449099867 scopus 로고    scopus 로고
    • Impact of fixed-dose combination drugs on adherence to prescription medications
    • Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23:611-614.
    • (2008) J Gen Intern Med. , vol.23 , pp. 611-614
    • Pan, F.1    Chernew, M.E.2    Fendrick, A.M.3
  • 72
    • 54049103635 scopus 로고    scopus 로고
    • Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects
    • Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168:1975-1983.
    • (2008) Arch Intern Med. , vol.168 , pp. 1975-1983
    • Bays, H.E.1    Goldberg, R.B.2    Truitt, K.E.3    Jones, M.R.4
  • 73
    • 49649095014 scopus 로고    scopus 로고
    • Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy
    • Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31:1479-1484.
    • (2008) Diabetes Care. , vol.31 , pp. 1479-1484
    • Fonseca, V.A.1    Rosenstock, J.2    Wang, A.C.3
  • 74
    • 49449087092 scopus 로고    scopus 로고
    • Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy
    • Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168:1531-1540.
    • (2008) Arch Intern Med. , vol.168 , pp. 1531-1540
    • Goldberg, R.B.1    Fonseca, V.A.2    Truitt, K.E.3    Jones, M.R.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.